poisar

Stocks · News reference

Moderna Vaccinates First Patients In Its Phase 1 Clinical Trial Of mRNA-1469 To Treat Bundibugyo Ebolavirus Following Health Canada Approval

BenzingaAug 4, 2026, 3:02 PMBenzinga Newsdesk

Moderna, Inc. (NASDAQ:MRNA) today announced that following Health Canada's authorization of the study, the first participants have been vaccinated in a Phase 1 clinical study in Canada evaluating mRNA-1469, the

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Aug 4, 2026, 3:02 PM
Checked
Aug 4, 2026, 3:02 PM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading